NCT07844070
A Study of Disease Modifying Therapy Use in Women With Multiple Sclerosis Before, During, and After Pregnancy
StatusActive, Not Recruiting
PhaseNot specified
SponsorNovartis Pharmaceuticals
Primary completion (estimated)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Study First Submitted
Endpoints
Primary
Proportion of Patients With ≥1 DMT Claim During the Pre-Conception Period
Timeframe: 6 months prior to the estimated conception date
Proportion of Patients With ≥1 DMT Claim During Pregnancy
Timeframe: Day 0 to 90 (Trimester 1), Day 91 to 181 (Trimester 2), Day 182 up to and including the day before the delivery date (Trimester 3), and Day 0 up to approximately Day 280 (pregnancy period)
Proportion of Patients With ≥1 DMT Claim During the Post-Delivery Period
Timeframe: Post-delivery 0 to 1.5 months, 1.5 to 3 months, 4 to 6 months, >6 months, up to approximately 4.5 years
Secondary (11)
Proportion of Patients by Demographic and Clinical Characteristics
DCCI Score
Number of PDG Mental Health Disorders
Age
Proportion of Patients by DMT Use During the Pre-Conception Period
Show 6 moreShow less
Proportion of Patients by DMT Use During Pregnancy
Proportion of Patients by DMT Use During the Post-Delivery Period
Proportion of Patients by Sequences of DMTs Used During the Pre-Conception Period
Proportion of Patients by Sequences of DMTs Used During Pregnancy
Proportion of Patients by Sequences of DMTs Used During the Post-Delivery Period
Time to First Observed DMT Claim in the Post-Delivery Period
Arms and interventions
MS Group
Women with MS who experienced at least one live birth between August 20, 2020 and September 30, 2024.
Sites
1 site in 1 country
- NovartisEast Hanover, New Jersey, United States